VaxGen to continue testing rPA102 anthrax vaccine based on promising trial results

By Elaine Rigoli

Tampa, Fla., Aug. 14 - VaxGen, Inc. announced that peer-reviewed data from the company's phase 1 clinical trial of its candidate anthrax vaccine rPA102, published in the journal Vaccine, demonstrated a clear relationship between the rPA102 dose administered and the subsequent immune response.

All injections were administered four weeks apart and at each dose level examined, three injections of the vaccine candidate yielded higher antibody titers than with two injections, according to a news release.

No clinically serious or dose-related toxicity was observed in this study.

"We need a better vaccine to help protect people from anthrax infection, whether the vaccine is given before or soon after exposure to anthrax spores. In this study we were able to demonstrate that the investigational anthrax vaccine produced an immune response that justifies further testing in larger studies. Data from this study will be used to help design strategies for testing this vaccine in the future," lead author of the paper, Geoffrey J. Gorse, said in the news release.

The phase 1 study was funded by VaxGen's contract N01-AI-25494 with the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health.

VaxGen is a biopharmaceutical company based in Brisbane, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.